Vaxcyte, Inc. $PCVX Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 28.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,250 shares of the company’s stock after buying an additional 13,250 shares during the quarter. Rock Springs Capital Management LP’s holdings in Vaxcyte were worth $3,501,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. Capital Advisors Ltd. LLC acquired a new stake in Vaxcyte in the 1st quarter valued at approximately $58,000. Finally, Allworth Financial LP increased its holdings in Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on PCVX. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Vaxcyte currently has an average rating of “Hold” and an average target price of $86.00.

Vaxcyte Stock Performance

Shares of PCVX opened at $55.50 on Tuesday. The stock has a 50-day simple moving average of $52.71 and a 200-day simple moving average of $54.71. The stock has a market capitalization of $8.01 billion, a PE ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the firm posted ($1.04) EPS. Analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.50, for a total value of $1,179,202.50. Following the sale, the chief executive officer directly owned 474,703 shares in the company, valued at approximately $24,921,907.50. This trade represents a 4.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 75,448 shares of company stock worth $4,091,197 in the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.